{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:08:36Z","timestamp":1793761716679,"version":"4.6.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001528","name":"Wellington Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001538","name":"Victoria University of Wellington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DA045884-01"],"award-info":[{"award-number":["DA045884-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DA046487-01"],"award-info":[{"award-number":["DA046487-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AA026949-01"],"award-info":[{"award-number":["AA026949-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["W81XWH-17-1-0256"],"award-info":[{"award-number":["W81XWH-17-1-0256"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Center for Clinical Pharmacology"},{"name":"St. Louis College of Pharmacy and Washington University to SM","award":["DA06241"],"award-info":[{"award-number":["DA06241"]}]},{"name":"NIH\/NCI Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.neuropharm.2019.02.010","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T08:10:27Z","timestamp":1550045427000},"page":"217-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats"],"prefix":"10.1016","volume":"150","author":[{"given":"Diana V.","family":"Atigari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Uprety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0060-6996","authenticated-orcid":false,"given":"Gavril W.","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susruta","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn M.","family":"Kivell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.02.010_bib1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.neubiorev.2010.10.012","article-title":"The predictive validity of the rat self-administration model for abuse liability","volume":"35","author":"O\u2019connor","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.neuron.2015.08.019","article-title":"Distinct subpopulations of nucleus accumbens dynorphin neurons drive aversion and reward","volume":"87","author":"Al-Hasani","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/164_2018_104","article-title":"Multifunctional opioid ligands","author":"Anand","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1208\/aapsj080114","article-title":"Opioid ligands with mixed \u03bc\/\u03b4 opioid receptor interactions: an emerging approach to novel analgesics","volume":"8","author":"Ananthan","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/jm010449i","article-title":"Evaluation of the Dmt\u2212 Tic pharmacophore: conversion of a potent \u03b4-Opioid receptor antagonist into a potent \u03b4 agonist and ligands with mixed properties","volume":"45","author":"Balboni","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2019.02.010_bib7","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1021\/jm0342358","article-title":"A bivalent ligand (KDN-21) reveals spinal \u03b4 and \u03ba opioid receptors are organized as heterodimers that give rise to \u03b41 and \u03ba 2 phenotypes. selective targeting of \u03b4\u2212 \u03ba heterodimers","volume":"47","author":"Bhushan","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/B978-0-12-420118-7.00010-X","article-title":"Mixed kappa\/mu partial opioid agonists as potential treatments for cocaine dependence","volume":"69","author":"Bidlack","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-013-3120-y","article-title":"The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research","volume":"229","author":"Bossert","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00213-010-1806-y","article-title":"Kinase cascades and ligand-directed signaling at the kappa opioid receptor","volume":"210","author":"Bruchas","year":"2010","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tips.2016.01.001","article-title":"New technologies for elucidating opioid receptor function","volume":"37","author":"Bruchas","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib12","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.1523\/JNEUROSCI.3769-07.2007","article-title":"Stress- induced p38 mitogen-activated protein kinase activation mediates \u03ba-opioid-dependent dysphoria","volume":"27","author":"Bruchas","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2009.08.062","article-title":"The dynorphin\/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors","volume":"1314","author":"Bruchas","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib14","doi-asserted-by":"crossref","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria","volume":"9","author":"Brust","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.105.092304","article-title":"Depressive-like effects of the \u03ba-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats","volume":"316","author":"Carlezon","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib16","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1523\/JNEUROSCI.4458-13.2014","article-title":"Opioid hedonic hotspot in nucleus accumbens shell: mu, delta, and kappa maps for enhancement of sweetness \u201cliking\u201d and \u201cwanting\u201d","volume":"34","author":"Castro","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-3-642-41199-1_14","article-title":"Arrestin-mediated activation of p38 MAPK:molecular mechanisms and behavioral consequences","volume":"219","author":"Chavkin","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","article-title":"Structure of the nanobody-stabilized active state of the kappa opioid receptor","volume":"172","author":"Che","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.neuropharm.2019.02.010_bib19","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1523\/JNEUROSCI.15-03-01714.1995","article-title":"The dopamine transporter: immunochemical characterization and localization in brain","volume":"15","author":"Ciliax","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib20","first-page":"888","article-title":"Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice","volume":"267","author":"Comer","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pnpbp.2015.01.001","article-title":"Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment","volume":"62","author":"Crowley","year":"2015","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2019.02.010_bib22","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/jm034234f","article-title":"A bivalent ligand (KDAN-18) containing \u03b4-antagonist and \u03ba-agonist pharmacophores bridges \u03b42 and \u03ba1 opioid receptor phenotypes","volume":"48","author":"Daniels","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib24","first-page":"1236","article-title":"Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies","volume":"266","author":"Devine","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aep129","article-title":"Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile","volume":"103","author":"Dietis","year":"2009","journal-title":"Br. J. Anaesth."},{"issue":"12","key":"10.1016\/j.neuropharm.2019.02.010_bib26","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/npp.2013.155","article-title":"\u03b2-endorphin via the delta opioid receptor is a major factor in the incubation of cocaine craving","volume":"38","author":"Dikshtein","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib28","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1523\/JNEUROSCI.2444-15.2015","article-title":"Kappa opioid receptor- induced aversion requires p38 MAPK activation in VTA dopamine neurons","volume":"35","author":"Ehrich","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib29","first-page":"30","article-title":"Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo","volume":"316","author":"Endoh","year":"1992","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib30","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00213-017-4637-2","article-title":"The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and \u03b2-tetrahydropyran Sal B, have anti-cocaine properties with minimal side- effects","volume":"234","author":"Ewald","year":"2017","journal-title":"Psychopharmacology (Berlin)"},{"issue":"2","key":"10.1016\/j.neuropharm.2019.02.010_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/76061","article-title":"Mice deficient for \u03b4-and \u03bc-opioid receptors exhibit opposing alterations of emotional responses","volume":"25","author":"Filliol","year":"2000","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.neuropharm.2019.02.010_bib32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cne.903590211","article-title":"Dopamine transporter immunoreactivity in rat brain","volume":"359","author":"Freed","year":"1995","journal-title":"J. Comp. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2019.02.010_bib33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pbb.2012.09.015","article-title":"Dopamine and glutamate release in the dorsolateral caudate putamen following withdrawal from cocaine self-administration in rats","volume":"103","author":"Gabriele","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1742-7843.2008.00306.x","article-title":"Antinociceptive and Adverse Effects of \u03bc\u2010and \u03ba\u2010Opioid Receptor Agonists: A Comparison of Morphine and U50488\u2010H","volume":"103","author":"Gallantine","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alcohol.2013.05.001","article-title":"Protracted withdrawal from ethanol and enhanced responsiveness stress: regulation via the dynorphin\/kappa opioid receptor system","volume":"47","author":"Gillett","year":"2013","journal-title":"Alcohol"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0006-8993(95)00306-B","article-title":"Kappa opioid inhibition of morphine and cocaine self-administration in rats","volume":"681","author":"Glick","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2005.11.034","article-title":"Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal","volume":"530","author":"G\u00f6ktalay","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib38","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1001\/jamapsychiatry.2017.2161","article-title":"Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"74","author":"Grant","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib39","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1046\/j.1471-4159.1999.0731066.x","article-title":"The K\u2010Opioid agonist, U\u201069593, decreases acute amphetamine\u2010evoked behaviors and calcium\u2010dependent dialysate levels of dopamine and glutamate in the ventral striatum","volume":"73","author":"Gray","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib40","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1021\/jm301543e","article-title":"Orvinols with mixed kappa\/mu opioid receptor agonist activity","volume":"56","author":"Greedy","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1139\/y98-017","article-title":"Opioid reward mechanisms: a key role in drug abuse?","volume":"76","author":"Herz","year":"1998","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2019.02.010_bib42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/adb.12206","article-title":"Effects of the kappa opioid receptor antagonist nor\u2010binaltorphimine (nor\u2010BNI) on cocaine versus food choice and extended\u2010access cocaine intake in rhesus monkeys","volume":"21","author":"Hutsell","year":"2016","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00213-012-2716-y","article-title":"Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice","volume":"226","author":"Jackson","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.tips.2007.06.009","article-title":"Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors","volume":"28","author":"Kenakin","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neuropharm.2014.07.016","article-title":"Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1\/2-dependent mechanism","volume":"86","author":"Kivell","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/B978-0-12-420118-7.00012-3","article-title":"Salvinorin A analogs and other kappa- opioid receptor compounds as treatments for cocaine abuse","volume":"69","author":"Kivell","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neuropharm.2008.07.043","article-title":"Neurobiological substrates for the dark side of compulsivity in addiction","volume":"56","author":"Koob","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/science.278.5335.52","article-title":"Drug abuse: hedonic homeostatic dysregulation","volume":"278","author":"Koob","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib52","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuropharm.2013.05.024","article-title":"Addiction as a stress surfeit disorder","volume":"76","author":"Koob","year":"2014","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2019.02.010_bib53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-2999(96)00961-2","article-title":"\u03ba-Opioid receptor agonist U50, 488H modulates cocaine and morphine self-administration in drug-naive rats and mice","volume":"321","author":"Kuzmin","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib54","doi-asserted-by":"crossref","first-page":"19168","DOI":"10.1073\/pnas.0910705106","article-title":"Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking","volume":"106","author":"Land","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alcohol.2009.05.001","article-title":"Blockade of ethanol reward by the kappa opioid receptor agonist U50, 488H","volume":"43","author":"Logrip","year":"2009","journal-title":"Alcohol"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of \u03ba-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib58","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/d41586-018-00045-1","article-title":"Strategy for making safer opioids bolstered","volume":"553","author":"Majumdar","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib60","first-page":"812","article-title":"Effects of kappa opioid agonists on cocaine-and food- maintained responding by rhesus monkeys","volume":"286","author":"Mello","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1749-6632.2000.tb06678.x","article-title":"Interactions between kappa opioid agonists and cocaine: preclinical studies","volume":"909","author":"Mello","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib62","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pbb.2009.09.002","article-title":"Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug- seeking in rats","volume":"94","author":"Morani","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib63","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/FBP.0b013e3283512c1e","article-title":"Single injection of novel kappa opioid receptor agonist salvinorin A attenuates expression of cocaine induced behavioral sensitization in rats","volume":"23","author":"Morani","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2013.10.050","article-title":"The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats","volume":"720","author":"Morani","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2019.02.010_bib65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/138161209787315594","article-title":"Designing multiple ligands-medicinal chemistry strategies and challenges","volume":"15","author":"Morphy","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib66","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.drugalcdep.2014.09.503","article-title":"Self-administration of oxycodone alone or as a mixture with the kappa agonist, salvinorin a, by monkeys under a progressive ratio schedule of reinforcement","volume":"146","author":"Naylor","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.02.010_bib67","first-page":"44","article-title":"Effects of kappa opioids on cocaine self-administration by rhesus monkeys","volume":"282","author":"Negus","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pbb.2006.05.002","article-title":"Cocaine self-administration under variable-dose schedules in squirrel monkeys","volume":"84","author":"Panlilio","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","article-title":"Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat","volume":"14","author":"Pellow","year":"1985","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib70","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib71","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1046\/j.1471-4159.1997.69031093.x","article-title":"A multisubstrate kinetic mechanism of dopamine transport in the nucleus accumbens and its inhibition by cocaine","volume":"69","author":"Povlock","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib72","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2011.06.008","article-title":"The delta opioid receptor: an evolving target for the treatment of brain disorders","volume":"32","author":"Pradhan","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00213-008-1122-y","article-title":"Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system","volume":"200","author":"Redila","year":"2008","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib75","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/j.1471-4159.2009.05910.x","article-title":"Rapid substrate\u2010induced down\u2010regulation in function and surface localization of dopamine transporters: rat dorsal striatum versus nucleus accumbens","volume":"108","author":"Richards","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib76","first-page":"1378","article-title":"Increases in drug and opioid overdose deaths\u2014United States, 2000\u20132014","volume":"64","author":"Rudd","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib77","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1254\/jphs.FPJ04014X","article-title":"Potential anxiolytic and antidepressant-like activities of SNC80, a selective. DELTA.-opioid agonist, in behavioral models in rodents","volume":"95","author":"Saitoh","year":"2004","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib78","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s002130051016","article-title":"U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking","volume":"144","author":"Schenk","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s002130000476","article-title":"Reinstatement of extinguished drug- taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593","volume":"151","author":"Schenk","year":"2000","journal-title":"Psychopharmacology (Berlin)"},{"issue":"7","key":"10.1016\/j.neuropharm.2019.02.010_bib80","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1523\/JNEUROSCI.18-07-02697.1998","article-title":"Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter","volume":"18","author":"Sesack","year":"1998","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2019.02.010_bib81","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0169-328X(92)90220-6","article-title":"Dopamine transporter mRNA: dense expression in ventral midbrain neurons","volume":"13","author":"Shimada","year":"1992","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib82","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharmthera.2007.06.011","article-title":"Dynorphin and the pathophysiology of drug addiction","volume":"116","author":"Shippenberg","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib83","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2174\/187152708786927813","article-title":"Targeting endogenous mu-and delta-opioid receptor systems for the treatment of drug addiction","volume":"7","author":"Shippenberg","year":"2008","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib84","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.biopsych.2008.09.009","article-title":"Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine","volume":"65","author":"Shippenberg","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib85","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bph.12692","article-title":"Pharmacology and anti-addiction effects of the novel kappa opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A","volume":"172","author":"Simonson","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib86","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0306-4522(01)00333-5","article-title":"Naloxone fails to produce conditioned place aversion in \u03bc-opioid receptor knock-out mice","volume":"106","author":"Skoubis","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib87","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1369-1600.2011.00317.x","article-title":"YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor\u2010knockout mice","volume":"17","author":"Song","year":"2012","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib88","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","article-title":"Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway","volume":"89","author":"Spanagel","year":"1992","journal-title":"Proc. Natl Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib89","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-328X(96)00249-5","article-title":"Prodynorphin, proenkephalin and \u03ba opioid receptor mRNA responses to acute \u201cbinge\u201d cocaine","volume":"44","author":"Spangler","year":"1997","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib90","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1254\/fpj.109.165","article-title":"Opioid receptor types and dependence","volume":"109","author":"Suzuki","year":"1997","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"1","key":"10.1016\/j.neuropharm.2019.02.010_bib91","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1021\/ml1001294","article-title":"A \u03ba opioid pharmacophore becomes a spinally selective \u03ba-\u03b4 agonist when modified with a basic extender arm","volume":"2","author":"Tang","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.neuropharm.2019.02.010_bib92","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0014-2999(94)90553-3","article-title":"U-50,488 blocks the development of morphine tolerance and dependence at a very low dose in guinea pigs","volume":"256","author":"Tao","year":"1994","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2019.02.010_bib93","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/bph.12810","article-title":"Anti\u2010nociception mediated by a \u03ba opioid receptor agonist is blocked by a \u03b4 receptor agonist","volume":"172","author":"Taylor","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib94","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/npp.2013.76","article-title":"Prefrontal cortical kappa- opioid receptor modulation of local neurotransmission and conditioned place aversion","volume":"38","author":"Tejeda","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"24","key":"10.1016\/j.neuropharm.2019.02.010_bib95","doi-asserted-by":"crossref","first-page":"9333","DOI":"10.1523\/JNEUROSCI.20-24-09333.2000","article-title":"\u03ba-Opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine","volume":"20","author":"Thompson","year":"2000","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.02.010_bib96","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.brainres.2005.11.005","article-title":"Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats","volume":"1069","author":"Torregrossa","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib98","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/acschemneuro.5b00153","article-title":"Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior","volume":"6","author":"V\u00e1radi","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib99","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/Corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit \u03b2-Arrestin-2","volume":"59","author":"V\u00e1radi","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.peptides.2007.10.012","article-title":"Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH (CH 2-COOH)-Bid (UFP- 512), a novel selective delta opioid receptor agonist","volume":"29","author":"Vergura","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib101","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety- related behavior in rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib102","first-page":"147","article-title":"Enadoline and butorphanol: evaluation of \u03ba-agonists on cocaine pharmacodynamics and cocaine self- administration in humans","volume":"299","author":"Walsh","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib103","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s002130100788","article-title":"Enadoline, a selective kappa opioid agonist:comparison with butorphanol and hydromorphone in humans","volume":"157","author":"Walsh","year":"2001","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib104","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00213-016-4292-z","article-title":"The anxiolytic-and antidepressant-like effects of ATPM-ET, a novel \u03ba agonist and \u03bc partial agonist, in mice","volume":"233","author":"Wang","year":"2016","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","article-title":"The role of the dynorphin\u2013\u03ba opioid system in the reinforcing effects of drugs of abuse","volume":"210","author":"Wee","year":"2010","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib106","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein\u2013biased \u03ba-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo","volume":"352","author":"White","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib107","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03033808","article-title":"Dopamine and reward: the anhedonia hypothesis 30 years on","volume":"14","author":"Wise","year":"2008","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib108","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1523\/JNEUROSCI.21-16-06338.2001","article-title":"Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission","volume":"21","author":"Wu","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib109","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1471-4159.2009.06478.x","article-title":"Inhibition of NAALADase by 2\u2010PMPA attenuates cocaine\u2010 induced relapse in rats: a NAAG\u2010mGluR2\/3\u2010mediated mechanism","volume":"112","author":"Xi","year":"2010","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.neuropharm.2019.02.010_bib110","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1124\/mol.105.012070","article-title":"Interaction of bivalent ligand KDN21 with heterodimeric \u03b4-\u03ba opioid receptors in HEK293 cells","volume":"68","author":"Xie","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.02.010_bib111","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0014-2999(88)90162-8","article-title":"A selective \u03ba-opioid agonist, U-50,488 H, blocks the development of tolerance to morphine analgesia in rats","volume":"156","author":"Yamamoto","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.010_bib112","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuroscience.2016.01.052","article-title":"p38 mitogen-activated protein kinase activation in amygdala mediates \u03ba opioid receptor agonist U50, 488H-induced conditioned place aversion","volume":"320","author":"Zan","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib113","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00213-003-1688-3","article-title":"Effect of the endogenous \u03ba opioid agonist dynorphin A (1\u201317) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL\/6J mice","volume":"172","author":"Zhang","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.02.010_bib114","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00213-003-1716-3","article-title":"Effect of the \u03ba opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL\/6J mice","volume":"173","author":"Zhang","year":"2004","journal-title":"Psychopharmacology (Berlin)"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818307573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818307573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:53:53Z","timestamp":1656118433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818307573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":110,"alternative-id":["S0028390818307573"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.010","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}